
As an Amazon Associate and affiliate partner, Menrva Books earns from qualifying purchases. Learn more
A paired-like homeodomain transcription factor 2 (PITX2) is another new marker in breast carcinoma when hypermethylation at P2 promoter of this gene was noted to be associated with poor prognostic factor. We investigated the expression of PITX2 protein using immunohistochemistry in invasive ductal carcinoma and its association with the established growth receptors such as ER, PR and HER2. As conclusion,PITX2 is another potential prognostic marker in breast carcinoma that able to add significant information to established prognostic factors of ER and PR. The expression of PITX2 together with PR may carry a very good prognosis.
This study investigates the prognostic significance of the DNA methylation marker PITX2 in breast carcinoma. The research examines the expression of PITX2 protein in invasive ductal carcinoma using immunohistochemistry and correlates it with established growth receptors like ER, PR, and HER2. The findings suggest that PITX2 is a potential prognostic marker that can provide additional valuable information when considered alongside ER and PR. Specifically, the co-expression of PITX2 and PR may indicate a very favorable prognosis.
This research paper presents findings on the role of PITX2 as a potential prognostic marker in breast carcinoma. The study's methodology, focusing on immunohistochemistry and correlation with established markers, provides a basis for its conclusions. The authority perspective suggests this work contributes to the understanding of breast cancer prognostication by identifying a marker that may enhance existing predictive models. The findings indicate that PITX2, particularly in conjunction with PR, could offer significant prognostic information for patient outcomes.
Page Count:
136
Publication Date:
2011-11-01
Publisher:
LAP Lambert Academic Publishing
ISBN-10:
3846599069
ISBN-13:
9783846599068
No comments yet. Be the first to share your thoughts!